Ajostu, Treagus’ comment that there was quite a profound difference between drug and placebo shown by the RBANS data echoes the following comment in the May/June edition of NeuroPerspective
…the hope is that the legacy of failure in therapeutics may be yet turned around via the parsing of the TBI population via such markers and the development of better endpoints. The recent negative trial findings from Neuren exemplify the dilemma: No impact on the GCOS-E was seen, yet a highly significant effect on a neuropsych test battery was provided by trofinetide.
I’m assuming that the editor was privy to the trial overview which was presented at the TBI Conference held on 12 May in Washington D.C.
http://www.niresearch.com/?p=560
AGM, page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |